Genetic association between cyclin D1 polymorphism and breast cancer susceptibility

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11959-11965

  Li, XiaoRui ^a   Huo, XiaoQing ^a   Li, WeiWei ^a   Yang, QingHui ^a   Wang, Ying ^a   Kang, XiaoChun ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cyclin D1; Polymorphism; Susceptibility

Indexed keywords

CYCLIN D1;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; SAMPLE SIZE; ALLELE; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; PUBLISHING; RISK;

ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYCLIN D1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; PUBLICATION BIAS;

EID: 84925287062     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2489-5     Document Type: Article

References (50)

1. Ormandy CJ et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003;78(3):323–35.
2. Motokura T et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350(6318):512–5.
3. Knudsen KE et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620–8.
4. Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol. 1992;8:529–61.
5. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther. 2002;1(3):226–31.
6. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7.
7. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002;4(1):14–7.
8. Ewen ME et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993;73(3):487–97.
9. Bala S, Peltomaki P. Cyclin D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61(16):6042–5.
10. Casson AG et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer. 2005;104(4):730–9.
11. Hou X et al. Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol. 2005;82(3):206–9.
12. Hung RJ et al. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. Cancer Res. 2006;66(16):8280–6.
13. Zheng Y et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis. 2001;22(8):1195–9.
14. Grieu F et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257–9.
15. Ceschi M et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis. 2005;26(8):1457–64.
16. Shu XO et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005;14(1):91–7.
17. Onay UV et al. Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer. 2008;8:6.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
21. Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
22. Abramson VG et al. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res. 2010;30(4):1279–85.
23. Labonte MJ et al. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012;23(6):1455–64.
24. Onay VU et al. SNP-SNP interactions in breast cancer susceptibility. BMC Cancer. 2006;6:114.
25. Al DA, Qureshi S, Al Saleh KA, Al Qahtani FH, Aleem A, AlSaif A, et al. Studies on the methods of diagnosis and biomarkersused in early detection of breast cancer in the Kingdom of Saudi Arabia: an overview. World J Med Sci. 2013;8(1):36–47.
26. Krippl P et al. The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82(3):165–8.
27. Forsti A et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep. 2004;11(4):917–22.
28. Yu CP et al. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat. 2008;107(1):95–102.
29. Naidu R, Yip CH, Taib NA. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma. 2008;55(2):87–95.
30. Driver KE et al. Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis. 2008;29(2):333–41.
31. Millar EK et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 2009;28(15):1812–20.
32. Yaylim-Eraltan I et al. Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo. 2009;23(5):767–72.
33. Justenhoven C et al. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer. 2009;124(9):2077–81.
34. Haiman CA et al. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the multiethnic cohort. BMC Cancer. 2009;9:43.
35. Canbay E et al. CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res. 2010;30(7):3093–8.
36. Jelonek K et al. Association between single-nucleotide polymorphisms of selected genes involved in the response to DNA damage and risk of colon, head and neck, and breast cancers in a Polish population. J Appl Genet. 2010;51(3):343–52.
37. Jeon S et al. Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer. Breast Cancer Res Treat. 2010;121(3):737–42.
38. Absenger, G., et al. (2013). A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog.
39. Bedewy AM et al. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer. J BUON. 2013;18(1):227–38.
40. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15(6):718–27.
41. Simpson JF et al. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997;151(1):161–8.
42. Gillett CE et al. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol. 1998;184(4):396–400.
43. Betticher DC et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11(5):1005–11.
44. Wu J et al. Identification of the cyclin D1b mRNA variant in mouse. Mol Biol Rep. 2009;36(5):953–7.
45. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63(21):7056–61.
46. Pabalan N et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2773–81.
47. Lu C et al. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;116(3):571–5.
48. Sergentanis TN, Economopoulos KP. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls. Mol Biol Rep. 2011;38(8):4955–63.
49. Cui J, Shen L, Wang Y. Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer Prev. 2012;13(10):5023–5.
50. Yang J et al. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects. Oncol Res. 2011;19(12):519–25.